AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-30. Numbers and descriptions here follow the published literature rather than marketing material.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Significance of research: The summary of the POPC simulations described above shows that the POPC system's initial area per lipid value was initially .65 ± .01 but it increases by more than 70% to 1.09 ± .03 at 10 mol% of ethanol which indicates the membrane begins to swell and expand as ethanol permeates through its exterior region. Due to the expansion of the membrane, the membrane thickness decreases from 3.83 ± .06 to 2.92 ± .05 which relates to the distance between the phosphorus atoms on opposite sides of the membrane. The study also supports the fact that ethanol prefers to bond just below the hydrophilic region of the phospholipids near the phosphate groups. The location of the ethanol creates a strong hydrogen bond between the water molecules. The results are depicted in the simulations and supported by mass density profiles as well. The mass density profiles show the location of the POPC lipids, water, and ethanol relevant to the hydrophobic core of the membrane and the concentration of ethanol. The mass density of ethanol increases as the concentration increases which indicates ethanol is moving towards the hydrophobic core of the membrane. The membrane becomes partially destroyed. The simulations also support that the interior of the membrane starts to become more hydrophilic due to the presence of water molecules in the interior region once the membrane is partially destroyed. The presence of ethanol also induced the formation of non-lamellar phases (non-bilayer) within the interior region (hydrophobic cored) of the phospholipid membrane.
On 21 March 2012, the Matazetas uploaded a video on the Blog del Narco. The recording, which is slightly over four minutes, shows several men dressed in black, with ski-masks and heavily armed; some of them (apparently the leaders) were sitting down at a table—as has been observed in other videos of the CJNG. In the communiqué, the men said that they will "clean up the states of Guerrero and Michoacán", and informed the federal government, the Armed Forces and the Federal Police that the CJNG has no problems with them. Then they went on to say that the CJNG was going to start a turf war "against the Knights Templar Cartel, who were reportedly "abusing innocent people" and operating through "kidnappings, extortion, protection racketeering, property theft, and rape." Vigilante groups consisting of local townspeople, known as autodefensas, had been taking arms against the Knights Templar for several years. Now, CJNG and local autodefensas are forming unprecedented alliances between the cartel and civilians in order to disrupt a common enemy. CJNG's significant funding allows them to supply the autodefensas with military-grade arms, changing the tide of the conflict between the Knights Templar and civilians. Consequently, both the autodefensas and CJNG are mutually benefitting as CJNG offers greater protection to victims of the Knights Templar while receiving support from the community in combatting a regional rival.
=== Rosenberg === Dr. Rosenberg (voiced by Jon St. John) is a scientist and a survivor of the Black Mesa incident. He first appears in Half-Life: Decay. When Gina Cross and Colette Green first arrive at the test chamber's control room and are receiving instructions from Dr. Keller, Rosenberg interrupts and voices his concern to Keller over having the anti-mass spectrometer run above 90% capacity, which is past the safety buffer zone for the equipment. Dr. Keller, however, dismisses his concern and states that the administrator's orders for this were clear. He tells Rosenberg that he can either stay and watch the experiment or return to his labs by the train yards. Rosenberg remains, and shortly thereafter the Resonance Cascade occurs. Immediately after the disaster, Rosenberg converses with Dr. Keller and makes it clear that he believes their greatest responsibility should be the safety of the people at Black Mesa. Although Keller thinks that they should attempt to reset the displacement fields first, he eventually agrees with Rosenberg, and they come up with a plan to contact the military, so that they can help and evacuate the facility as soon as possible. Gina and Colette escort Rosenberg through the Hazard Course to a satellite communications center on the surface, where he is able to transmit a distress signal. Dr. Rosenberg decides to wait there for the military, and this is the last time he is seen in Decay as Gina and Colette return below to assist Dr. Keller. However, his voice is heard once more in the game later on.
=== Neurotransmission === Inhibitory neurons in the central nervous system play a homeostatic role in the balance of neuronal activity between excitation and inhibition. Inhibitory neurons using GABA, make compensating changes in the neuronal networks preventing runaway levels of excitation. An imbalance between excitation and inhibition is seen to be implicated in a number of neuropsychiatric disorders.
=== Starbucks card and loyalty program === In May 2008, a loyalty program was introduced for registered users of the Starbucks Card (previously simply a gift card) offering perks such as free Wi-Fi Internet access, no charge for soy milk and flavored syrups, and free refills on brewed drip coffee, iced coffee, or tea. Each time a customer purchases a drink, they earn stars if they present their rewards card or scan their card from the mobile app. Eventually, these stars accumulate to allow customers to redeem for perks such as free drinks, free add-ins, free bakery items or selected merchandise. In 2009, Starbucks began beta testing its mobile app for the Starbucks card, a stored value system in which consumers access pre-paid funds to purchase products at Starbucks. Starbucks released its complete mobile platform in January 2011. By December 2011, the number of mobile transactions exceeded 26 million.
Sources: en.wikipedia.org
The 2015 Australian Football League draft consisted of the various periods where the 18 clubs in the Australian Football League (AFL) can trade and recruit players following the completion of the 2015 AFL season. Additions to each club's playing list are not allowed at any other time during the year. The key dates for the trading and drafting periods were:
As it gained popularity, opium, and after 1820, morphine, was mixed with a wide variety of agents, drugs and chemicals including mercury, hashish, cayenne pepper, ether, chloroform, belladonna, whiskey, wine and brandy."
=== Elimination === Pentamidine has an average half-life of five to eight hours when given intravenously and seven to eleven hours when given intramuscularly. However, these may increase with severe kidney problems. Pentamidine can remain in the system for as long as eight months after the first injection.
In Ecuador, anti-Peruvian sentiment is mainly related to irredentism due to the Gran Colombia–Peru War and the border conflict between the two countries. According to former ambassador Eduardo Ponce Vivanco, the violent anti-Peruvianism cultivated in Ecuador is comparable to the anti-Chileanism that subsists in a minority in Peru. The Ecuadorian government came to describe Peru as the "Cain of the Americas" due to its border disputes, in the first years after the signing of the Rio de Janeiro Protocol on 29 January 1942, a treaty that established the borders; in the Ecuadorian streets, phrases such as "Peruvian imperialism" were read. The governments of José María Velasco Ibarra, León Febres Cordero and Jaime Roldós Aguilera had an openly anti-Peruvian position.
== Oxygen-18 == Oxygen-18 (18O, Ω) is one of the stable isotopes of oxygen, with roughly 0.20% abundance, and considered one of the environmental isotopes. Most 18O is produced when 14N (made abundant from CNO burning) captures a 4He nucleus, becoming 18F. This quickly (half-life around 110 minutes) beta decays to 18O making that isotope common in the helium-rich zones of stars. Temperatures on the order of 109 kelvins are needed to fuse oxygen into sulfur. Fluorine-18 is usually produced by irradiation of 18O-enriched water with high-energy (about 18 MeV) protons prepared in a cyclotron or a linear accelerator, yielding an aqueous solution containing 18F as fluoride ion. This solution is then used for rapid synthesis of a labeled molecule, often with the fluorine atom replacing a hydroxy group. The labeled molecules or radiopharmaceuticals have to be synthesized after the radiofluorine is prepared, as the high energy proton radiation would destroy the molecules. Large amounts of oxygen-18 enriched water are used in positron emission tomography centers, for on-site production of 18F-labeled fluorodeoxyglucose (FDG). Measurements of the 18O/16O ratio (known as δ18O) are often used in paleoclimatology. Water molecules with a lighter isotope are slightly more likely to evaporate and less likely to fall as precipitation, so Earth's freshwater and polar ice have slightly less (0.1981%) 18O than air (0.204%) or seawater (0.1995%). This disparity allows the study of historical temperature patterns via the analysis of ice cores.
Sources: en.wikipedia.org
== Safety and side effects == Some anti-obesity medications can have severe, even lethal side effects, fen-phen being a famous example. Fen-phen was reported through the FDA to cause abnormal echocardiograms, heart valve problems, and rare valvular diseases. Out of 25 anti-obesity medications withdrawn from the market between 1964 and 2009, 23 acted by altering the functions of chemical neurotransmitters in the brain. The most common side effects of these drugs that led to withdrawals were mental disturbances, cardiac side effects, and drug abuse or drug dependence. GLP-1 receptor agonists are known to have common side effects including nausea and vomiting. Deaths were associated with seven products. Ephedra was removed from the US market in 2004 over concerns that it raises blood pressure and could lead to strokes and death.
The investigation had found out that in the period of 2004-2009, Gobozov was giving secret information on the deployment the military units of the Russian Ministry of Defence and the Border Service of the FSB on the South Ossetian territory to the secret services of Georgia. However, according to the agreement between Russia and Georgia, only the presence of the Russian contingent of the Joint Peacekeeping Forces was allowed in South Ossetia and their number, staff composition, equipment, places of deployment and every movement should have been known to Tbilisi. Thus, the Prosecutor General's Office of the Russian Federation admitted that non-peacekeeping Russian troops were present on the South Ossetian territory (which Russia then considered as the Georgian territory) without Tbilisi's consent before the war in August 2008. Russian journalist Yulia Latynina commented that by acknowledging the presence of the Russian troops on the de jure Georgian territory from 2004 to 2008, the Prosecutor General's Office of Russia admitted the crime of aggression of Russia. In 2012, Anatoly Khrulyov, the commander of the 58th Army, said in an interview that "For me, the war began in my workplace." He said that the decision to reinforce the Russian peacekeeping force was made on 5 August 2008. Khrulyov said that Marat Kulakhmetov, commander of the Joint Peacekeeping Forces called him on the night of 7–8 August and said that General Mamuka Kurashvili had warned him that Georgia was going to launch a large-scale military operation.
Good agricultural practice (GAP), for farming and ranching Good clinical practice (GCP), for hospitals and clinicians conducting clinical studies on new drugs in humans Good distribution practice (GDP) deals with the guidelines for the proper distribution of medicinal products for human use. Good laboratory practice (GLP), for laboratories conducting non-clinical studies (toxicology and pharmacology studies in animals) Good pharmacovigilance practice (GVP), for the safety of produced drugs Good regulatory practice (GRP), for the management of regulatory commitments, procedures and documentation Collectively, these and other good-practice requirements are referred to as "GxP" requirements, all of which follow similar philosophies. Other examples include good guidance practice and good tissue practice.
HCTU is an amidinium coupling reagent used in peptide synthesis. It is analogous to HBTU. The HOBt moiety has a chlorine in the 6 position which improves reaction rates and the synthesis of difficult couplings HCTU and related reagents containing the 6-chloro-1-hydroxybenzotriazole moiety can be prepared by reaction with TCFH under basic conditions. It can exist in an N-form (guanidinium) or an O-form (uronium), but the N-form is generally considered to be more stable for this class of reagent. In vivo dermal sensitization studies according to OECD 429 confirmed HCTU is a strong skin sensitizer, showing a response at 0.50 wt% in the Local Lymph Node Assay (LLNA) placing it in Globally Harmonized System of Classification and Labelling of Chemicals (GHS) Dermal Sensitization Category 1A.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.